Edwards Lifesciences reported third-quarter net sales of $1.72 billion, a 10.5% increase from the prior year, driven by an 8.0% rise in TAVR sales to $1.24 billion and a 44.0% surge in TMTT sales to $207 million. The company raised its full-year 2026 total sales growth guidance to approximately 11.5%, up from the previous range of 10% to 11%. Adjusted earnings per share for the quarter were $0.80, reflecting a 19% increase year-over-year. Management also increased TAVR sales growth guidance to 9.0%-9.5% and TMTT sales guidance to $780-$790 million. Edwards Lifesciences is a leading global structural heart innovation company.
